Tongji University Medical College
Shanghai, China
NCT Number: NCT01044680
The purpose of this study was to determine the effects of NUTRIOSE® supplementation on body composition, satiety, and determinants of metabolic syndrome in overweight men.
Looking for future studies?
Notify Me20 year–35 year
Male
Interventional
Phase 2 / Phase 3
Shanghai, China
Previous trials of fiber supplementation have yielded equivocal results on body composition, satiety, and determinants of metabolic syndrome. This double-blind, randomized, placebo-controlled study was conducted to determine the effects of a proprietary soluble dextrin dietary fiber supplement (NUTRIOSE®) on these parameters in overweight males.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
17 grams of NUTRIOSE consumed twice daily for 12 weeks
17 g maltodextrin consumed twice daily for 12 weeks
Time frame: 12 weeks
Roquette Freres
Industry
The Effects of NUTRIOSE®FB Dietary Fiber Supplementation on the Satiety, Body Fat Distribution, and Metabolic Syndrome Biomarkers of Overweight Adult Chinese Men 20-35 Years of Age.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06641596
Body Weight, Glucose Metabolism Disorders
College Station, Texas, United States
View Trial DetailsNCT01428791
Behavior, Behavioral Symptoms
Chicago, Illinois, United States
View Trial DetailsNCT00455325
Arterial Occlusive Diseases, Arteriosclerosis
St Louis, Missouri, United States
View Trial DetailsNCT00455403
Arterial Occlusive Diseases, Arteriosclerosis
St Louis, Missouri, United States
View Trial Details